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A b s t r A c t
A permanent pacemaker is commonly required in patients undergoing transcatheter 
aortic valve implantation (TAVI) at ranges up to 30-50%. In general, the incidence is 
higher with the self- vs balloon-expandable valves. Several risk factors have been iden-
tified. Importantly, pacemaker implantation does not seem to improve prognosis and 
this needs to be further explored. Finally, new generation valves appear to increase 
the complication of AV block and need for permanent pacing. These issues are herein 
briefly reviewed.
I n t r o d u c t I o n
High-degree or complete atrioventricular (AV) block requiring permanent pacing 
is a well-known complication of surgical aortic valve replacement (AVR) due to injury 
of the AV conduction system incurred during surgery. Over the recent years, we have 
also become poignantly aware that there is a similar risk for a need for a permanent 
pacemaker in patients undergoing transcatheter aortic valve implantation (TAVI).1 
Although there is no tissue excision involved during TAVI as in AVR to explain the 
injury of the AV conduction system, it appears that such injury still occurs with com-
pression of adjacent tissue by both the balloon and the stent of the new valve during 
TAVI. Furthermore, it appears that the need for pacing is higher after TAVI than after 
AVR.2 In addition, among the TAVI patients, those receiving the self-expandable valve 
appear to have a higher risk compared to those receiving the balloon expandable valve.3
According to a recent review, the rate of permanent pacemaker implantation aver-
ages approximately 17% with a wide variation (from 2-51%). In general, the incidence 
is higher with the self-expanding valve (~28%) compared with the balloon-expandable 
valve (~6%).4
r I s k  f A c t o r s  ( t A b l e  1 )
As stated above, the self-expandable type of prosthesis has been associated with 
higher risk of pacemaker implantation.3,5 Balloon pre-dilatation has also been shown 
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to confer a high pacemaker risk.5 Furthermore, in several 
studies, pre-existing right bundle branch block (RBBB) is an 
independent predictor of complete AV block after TAVI.3,5,6 
Another risk factor relates to the depth of valve implantation, 
which may lead to AV block when greater than 6 mm for the 
self-expandable valve.3,7 Similarly, for the balloon-expandable 
valves, low implantation depth (mean 7 mm vs 3.5 mm of 
the inflow to annulus distance) is associated with clinically 
significant new conduction disturbances and permanent pace-
maker implantation.8 Some have suggested to measure the AV 
membranous septum (MS) length by computed tomography 
(CT) as an anatomic surrogate of the distance between the 
aortic annulus and the bundle of His in an attempt to identify 
patient-specific anatomic risk of high-degree AV block.9 In 
patients with valve-in-valve procedures there appears to be a 
higher risk for a pacemaker.10 
According to the large PARTNER trial registry of the bal-
loon expandable valves, a new pacemaker was required in 173 
of 1,973 patients (8.8%).11 In addition to pre-existing RBBB, 
the prosthesis to left ventricular outflow tract diameter ratio 
and the left ventricular end-diastolic diameter were identi-
fied as predictors of pacemaker implantation. Furthermore, 
a new pacemaker was associated with a longer duration of 
hospitalization and more repeat hospitalizations and higher 
mortality at 1 year.
According to data obtained from a meta-analysis of 41 
studies that included 11,210 TAVI patients, of whom 17% 
required a pacemaker, male gender, baseline conduction 
disturbances, and intraprocedural AV block emerged as pre-
dictors of pacemaker implantation after TAVI.12 
New-onset LBBB may develop in about 30% of patients 
undergoing TAVI. In one study, patients with persistent 
LBBB and no pacemaker implantation at hospital discharge 
had a higher incidence of syncope (16% vs 0.7%; p=0.001) 
and complete AV block requiring a pacemaker (20% vs 0.7%; 
p <0.001), but not of global mortality or cardiac mortality 
during the follow-up period (all, p >0.20).13 New-onset LBBB 
was the only factor associated with pacemaker implantation 
following TAVI.13 Some have suggested that measurement of 
the HV interval in this group of patients with development of 
new-onset LBBB can guide pacemaker implantation when the 
postprocedural HV interval is >65 ms.14 Other studies have 
indicated an adverse prognosis with increased mortality in 
patients with new-onset LBBB.15 However, in another study, 
new-onset LBBB, although it persisted in most patients, it was 
not a predictor of overall or cardiovascular mortality or perma-
nent pacemaker implantation.16 Finally, there are no definite 
recommendations regarding the management of new-onset 
LBBB after TAVI by international societies, which leaves room 
for an individualized approach and strategy for such patients. 
The question remains whether these patients should receive a 
pacemaker, and whether a biventricular pacemaker would be a 
better choice. Future studies will need to explore these options. 
c l I n I c A l  o u t c o m e
Some data indicate that prognosis is not favorably affected 
in patients receiving a pacemaker after TAVI.17 A likely ex-
planation for this discrepancy may relate to the deleterious 
consequences of right ventricular pacing which may negate any 
beneficial effect of pacing.18 There are no studies comparing 
the effect of the RV pacing site in this population or the ef-
fects of right ventricular vs biventricular pacing. Contrariwise, 
other studies have indicated, as already mentioned above, 
that a new pacemaker is associated with a longer duration of 
hospitalization and more repeat hospitalizations and higher 
mortality at 1 year.11 Others have reported an unfavorable 
hemodynamic impact of a pacemaker (reduced ejection frac-
tion and impaired left ventricular unloading), however without 
affecting 2-year clinical outcome.19 It appears that although 
ejection fraction improves after TAVI in patients with severe 
aortic stenosis in patients in the absence of new conduction 
defects, in patients with a new conduction defect after TAVI, 
there appears that no such improvement in ejection fraction 
is observed at follow-up.20 
In patients with preexisting or new-onset LBBB, there 
is a higher risk of developing high-degree AV block, some 
investigators recommend intensified monitoring, especially 
in patients treated with the self-expandable valve.21 A recent 
meta-analysis confirms that new-onset LBBB post-TAVI is a 
marker of increased risk of cardiac death and need for pace-
maker at 1-year follow-up.22
n e W  V A l V e s
Although the advent of new valves has facilitated the proce-
dure and has reduced paravalvular leaks, the rate of pacemaker 
implantation has rather been adversely affected, especially 
tAble 1. Risk Factors for AV Block During TAVI
• Preexisting RBBB
• Self-expandable prosthesis
• Depth of valve implantation 
• LVOT oversizing 
• Prosthesis overexpansion 
• Valve-in-valve procedure
• New-onset LBBB
 post-procedural HV interval of >65 ms
• New generation valves
AV = atrioventricular; LBBB = left bundle branch block; LVOT = left 
ventricular outflow tract; RBBB = right bundle branch block.
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when associated with a lower implantation height.23 Thus, the 
most recent experience has indicated that newer generation 
devices together with valve oversizing relative to the left ven-
tricular outflow tract, and deeper valve implants are associated 
with a higher need for pacemaker implantation after TAVI.24
c o n c l u s I o n
The rate of permanent pacemaker implantation averages 
approximately 17% with a wide variation (from 2-51%). In 
general, the incidence is higher with the self-expanding valve 
(~28%) compared with the balloon-expandable valve (~6%). 
Among others, important high-risk factors include preexisting 
RBBB, low implantation depth of the valve, new-onset LBBB 
and intraprocedural AV block. Counterintuitively, permanent 
pacemaker implantation does not seem to improve prognosis 
and this needs to be further considered in terms of the type of 
pacing performed, such as right ventricular vs biventricular pac-
ing, in light of evidence of deleterious effects of right ventricular 
apical pacing. Finally, new generation valves appear to increase 
the complication of AV block and need for permanent pacing.
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